Mutations in AKT1, AKT3, PIK3CA, PIK3CG, PIK3R2, or PHLPP1, as well as PTEN loss, or the overexpression of multiple receptor tyrosine kinases, including epidermal growth factor receptors (EGFRs), insulin-like growth factor 1 receptors, platelet-derived growth factor receptors α and β, or fibroblast growth factor receptor 3 have been reported in resistant melanoma tumors [86]. The gene discussed is IGF1R; the disease is melanoma.